The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Wall Street Beat | Earnings Reports | Funding Roundup | Mergers & Acquisitions | Initial Public Offerings | Legal News
The U.S. Navy is furious that the federal Food & Drug Administration repeatedly spiked clinical trials of Biopure Corp.‘s Hemopure blood substitute, according to an internal Navy report obtained by The Boston Globe.
The Navy wants to examine whether Hemopure can be used on the battlefield to treat combat injuries when blood transfusions aren’t available.
Bruker Group acquired a German subsidiary of Varian Medical Systems for an undisclosed amount.
Bruker, which has operations in Billerica, closed the deal April 1 for Accel Instruments GmbH, a division of Varian that makes research instruments and proton therapy devices.
Doctors in the United Kingdom successfully performed the first surgery using proprietary technology made by I-Therapeutix Inc.
The Waltham-based ophthalmology firm makes the I-Zip ocular bandage, a synthetic hydrogel composed mostly of water. It’s applied as a liquid, but morphs into a soft, protective barrier which then breaks down into tears when the therapy is complete.
The company has CE-Mark approval to market the product in the European Union and is awaiting regulatory clearance in the United States.
Amicas Inc. closed its $39 million buyout of Emageon Inc. after the Birmingham, Ala.-based medical imaging software firm settled a lawsuit with shareholders trying to block the deal.
Boston-based Amicas, which provides medical imaging software and services, said the deal, for which it paid $1.82 per share to Emageon stockholders, expands its footprint in the healthcare IT field and makes the company a leader in the imaging and information business with a combined 1,000 customers.
Charles River Laboratories International Inc. agreed to acquire Piedmont Research Center LLC from PPD Inc. for $46 million in cash.
Wilmington, N.C.-based PRC provides preclinical discovery services in oncology and other therapeutic areas.
The Wilmington, Mass.-based lab services provider said the deal, expected to close during the second quarter, expands its reach into the pharmaceutical and biotech oncology treatment sphere.
Haemonetics Corp. acquired Altivation Software for an undisclosed amount.
Chico, Calif.-based Altivation provides blood bank management software.
The Braintree blood management products maker said the deal complements its existing platforms and adds the ability to manage mobile blood drives. The company plans to roll Altivation into its Haemonetics Software Solutions business, but keep its operations in Chico.
Hologic Inc. lost an anti-trust case against Qiagen Gaithersburg Inc.
The Bedford women’s health product manufacturer’s lawsuit alleging that the Dutch diagnostics firm violated federal anti-trust laws was denied (PDF) by the U.S. Court of Appeals for the Federal Circuit.
In response to a patent infringement suit filed against Hologics’ Third Wave Technologies division by Qiagen (then known as Digene Corp.) in January 2007, Hologics filed the anti-trust suit.
Thermo Fisher Scientific inked a five-year distribution deal with British diagnostics maker Osmetech plc that will see the Waltham lab instruments manufacturer distribute some Osmetech products.
Fisher’s HealthCare division will sell Osmetech’s eSensor XT-8 instrument platform and molecular diagnostic tests and consumables in the United States.
Defective batteries and a software glitch in one of Zoll Medical Corp.‘s defibrillators may have killed two people, the Chelmsford device maker warned.
Zoll issued a “voluntary worldwide field corrective action” on its AED Plus automated external defibrillator after discovering the problem.
Stockholders of Orthofix International NV fought back a proxy challenge by a New York-based hedge fund.
The McKinney, Texas-based orthopedic device manufacturer said its shareholders beat back an attempt by Ramius LLC to oust four current board members and install their own people.
Orthofix also runs offices in Boston and a production facility in Springfield.
GE and Intel Corp. are in the healthcare business — big time.
The twin colossi will spend $250 million over five years to develop products to remotely monitor patients’ health. The growing field, called “telemedicine” or “e-health,” allows physicians to remotely evaluate, diagnose and treat patients outside of the doctor’s office.
News of the deal broke yesterday, but the companies made the official announcement at a press conference today in New York.
